Compare Ginkgo Bioworks Holdings Inc (DNA) vs Norfolk Southern Corporation (NSC) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Norfolk Southern (NSC) trades at $317.14, up 1.26% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $361.86. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Strong profitability is evidenced by a 21.02% net income margin and 16.97% ROE, while news highlights significant institutional investment and progress on the proposed merger with Union Pacific.

The outlook is positive, supported by earnings momentum and potential merger benefits, but risks include integration challenges, fuel cost pressures noted in recent news, and a relatively high P/E ratio of 27.05. The stock offers a dividend yield and growth potential, contingent on successful execution of strategic initiatives.